Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party.
Kim DJ, Lee HS, Moon JH, Sohn SK, Kim HJ, Cheong JW, Jo DY, Kim H, Lee H, Bang SM, Lee WS, Park Y, Lee MH, Lee JH, Bae SH, Kim MK; Korean Society of Hematology AML/MDS Working Party.
Kim DJ, et al. Among authors: lee h, lee hs, lee mh, lee ws, lee jh.
Oncotarget. 2017 May 29;8(45):79414-79424. doi: 10.18632/oncotarget.18258. eCollection 2017 Oct 3.
Oncotarget. 2017.
PMID: 29108320
Free PMC article.